How sleep affects immunotherapy for lung cancer
Part of Brain & nervous system, Cancer, Lungs & breathing, Mental health clinical trials.
This study looks at how sleep problems affect immunotherapy for people with lung cancer. If you have non-small-cell lung cancer and are about to start immunotherapy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small-cell lung cancer (stage II to IV).
- You are 18 years old or older.
- You are planning to start immunotherapy (like nivolumab or pembrolizumab).
- You can understand and agree to participate in the study.
- You do not have serious mental illness (like major depression), and you have not had recent chemotherapy or radiation.
- You do not have other serious health problems like heart disease or severe kidney or liver issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how the immune system responds to immunotherapy in people with advanced non-small cell lung cancer. By collecting sputum (mucus from your lungs) and blood samples, researchers hope to find clues that could help predict treatment outcomes.
This study looks at how sleep problems affect your body's immune response to lung cancer. It aims to find links between sleep and the tumor environment, which could help improve treatment.
This study looks at how sleep disturbances affect how well lung cancer treatments work. It may help doctors understand if improving sleep can lead to better treatment results.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial looks at how sleep patterns affect how well immunotherapy works before surgery for people with stomach or gastroesophageal junction cancer. Researchers want to understand if sleep quality is linked to better treatment response.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.